Susan Moran, M.D. most recently served as chief medical officer of RayzeBio, until its acquisition in 2024 by Bristol Myers Squibb. Dr. Moran currently serves on the board of directors of Tyra Biosciences and BioAtla, both publicly traded clinical-stage biotechnology companies. She was previously chief medical officer at QED Therapeutics and prior to that, led clinical development at Puma Biotechnology. Dr. Moran received an M.D. from Duke University, and an MS in clinical epidemiology from the University of Pennsylvania School of Medicine. She received a BA in chemistry from the University of Virginia.